No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 593 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies July 10, 2019 EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal September 1, 2022 How to Make a Homemade Face Mask from a Folded Scarf—No... April 29, 2020 First Global Estimates of Cervical Cancer Attributable to HIV November 30, 2020 Load more HOT NEWS ESMO Breast Cancer Congress 2022 An integral part of research Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... Wawa Employee Saves Life Of Customer Who Stopped Breathing After A...
